ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global HIV and AIDS Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-17L17658
Home | Market Reports | Health| Reproductive Health
Global HIV and AIDS Vaccine Market Research Report 2024
BUY CHAPTERS

Global HIV and AIDS Vaccine Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-17L17658
Report
October 2025
Pages:141
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Johnson and Johnson (Janssen)
Sanofi Pasteur
Uvax Bio
IAVI
AELIX Therapeutics
HKUMed

HIV and AIDS Vaccine Market

The global HIV and AIDS Vaccine market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
From a downstream perspective, Viral Vector Vaccines accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
HIV and AIDS Vaccine leading manufacturers including Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc., dominate supply; the top five capture approximately % of global revenue, with Johnson and Johnson (Janssen) leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global HIV and AIDS Vaccine market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of HIV and AIDS Vaccine Market Report

Report Metric Details
Report Name HIV and AIDS Vaccine Market
Segment by Type
  • Preventive Vaccine
  • Therapeutic Vaccine
Segment by Application
  • Viral Vector Vaccines
  • Recombinant Protein Vaccines
  • Nucleic Acid Vaccines (including mRNA Vaccines)
  • Other Vaccines
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the HIV and AIDS Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the HIV and AIDS Vaccine Market report?

Ans: The main players in the HIV and AIDS Vaccine Market are Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed

What are the Application segmentation covered in the HIV and AIDS Vaccine Market report?

Ans: The Applications covered in the HIV and AIDS Vaccine Market report are Viral Vector Vaccines, Recombinant Protein Vaccines, Nucleic Acid Vaccines (including mRNA Vaccines), Other Vaccines

What are the Type segmentation covered in the HIV and AIDS Vaccine Market report?

Ans: The Types covered in the HIV and AIDS Vaccine Market report are Preventive Vaccine, Therapeutic Vaccine

1 Study Coverage
1.1 Introduction to HIV and AIDS Vaccine: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global HIV and AIDS Vaccine Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Preventive Vaccine
1.2.3 Therapeutic Vaccine
1.3 Market Segmentation by Application
1.3.1 Global HIV and AIDS Vaccine Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Viral Vector Vaccines
1.3.3 Recombinant Protein Vaccines
1.3.4 Nucleic Acid Vaccines (including mRNA Vaccines)
1.3.5 Other Vaccines
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global HIV and AIDS Vaccine Revenue Estimates and Forecasts 2020-2031
2.2 Global HIV and AIDS Vaccine Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global HIV and AIDS Vaccine Sales Estimates and Forecasts 2020-2031
2.4 Global HIV and AIDS Vaccine Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global HIV and AIDS Vaccine Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global HIV and AIDS Vaccine Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Preventive Vaccine Market Size by Manufacturers
3.5.2 Therapeutic Vaccine Market Size by Manufacturers
3.6 Global HIV and AIDS Vaccine Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global HIV and AIDS Vaccine Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global HIV and AIDS Vaccine Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global HIV and AIDS Vaccine Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global HIV and AIDS Vaccine Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America HIV and AIDS Vaccine Sales and Revenue by Type (2020-2031)
6.4 North America HIV and AIDS Vaccine Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America HIV and AIDS Vaccine Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe HIV and AIDS Vaccine Sales and Revenue by Type (2020-2031)
7.4 Europe HIV and AIDS Vaccine Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe HIV and AIDS Vaccine Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific HIV and AIDS Vaccine Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific HIV and AIDS Vaccine Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific HIV and AIDS Vaccine Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America HIV and AIDS Vaccine Sales and Revenue by Type (2020-2031)
9.4 Central and South America HIV and AIDS Vaccine Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America HIV and AIDS Vaccine Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa HIV and AIDS Vaccine Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa HIV and AIDS Vaccine Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa HIV and AIDS Vaccine Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Johnson and Johnson (Janssen)
11.1.1 Johnson and Johnson (Janssen) Corporation Information
11.1.2 Johnson and Johnson (Janssen) Business Overview
11.1.3 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Product Models, Descriptions and Specifications
11.1.4 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales by Product in 2024
11.1.6 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales by Application in 2024
11.1.7 Johnson and Johnson (Janssen) HIV and AIDS Vaccine Sales by Geographic Area in 2024
11.1.8 Johnson and Johnson (Janssen) HIV and AIDS Vaccine SWOT Analysis
11.1.9 Johnson and Johnson (Janssen) Recent Developments
11.2 Sanofi-Pasteur
11.2.1 Sanofi-Pasteur Corporation Information
11.2.2 Sanofi-Pasteur Business Overview
11.2.3 Sanofi-Pasteur HIV and AIDS Vaccine Product Models, Descriptions and Specifications
11.2.4 Sanofi-Pasteur HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi-Pasteur HIV and AIDS Vaccine Sales by Product in 2024
11.2.6 Sanofi-Pasteur HIV and AIDS Vaccine Sales by Application in 2024
11.2.7 Sanofi-Pasteur HIV and AIDS Vaccine Sales by Geographic Area in 2024
11.2.8 Sanofi-Pasteur HIV and AIDS Vaccine SWOT Analysis
11.2.9 Sanofi-Pasteur Recent Developments
11.3 Uvax Bio
11.3.1 Uvax Bio Corporation Information
11.3.2 Uvax Bio Business Overview
11.3.3 Uvax Bio HIV and AIDS Vaccine Product Models, Descriptions and Specifications
11.3.4 Uvax Bio HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Uvax Bio HIV and AIDS Vaccine Sales by Product in 2024
11.3.6 Uvax Bio HIV and AIDS Vaccine Sales by Application in 2024
11.3.7 Uvax Bio HIV and AIDS Vaccine Sales by Geographic Area in 2024
11.3.8 Uvax Bio HIV and AIDS Vaccine SWOT Analysis
11.3.9 Uvax Bio Recent Developments
11.4 AELIX Therapeutics
11.4.1 AELIX Therapeutics Corporation Information
11.4.2 AELIX Therapeutics Business Overview
11.4.3 AELIX Therapeutics HIV and AIDS Vaccine Product Models, Descriptions and Specifications
11.4.4 AELIX Therapeutics HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 AELIX Therapeutics HIV and AIDS Vaccine Sales by Product in 2024
11.4.6 AELIX Therapeutics HIV and AIDS Vaccine Sales by Application in 2024
11.4.7 AELIX Therapeutics HIV and AIDS Vaccine Sales by Geographic Area in 2024
11.4.8 AELIX Therapeutics HIV and AIDS Vaccine SWOT Analysis
11.4.9 AELIX Therapeutics Recent Developments
11.5 IAVI
11.5.1 IAVI Corporation Information
11.5.2 IAVI Business Overview
11.5.3 IAVI HIV and AIDS Vaccine Product Models, Descriptions and Specifications
11.5.4 IAVI HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 IAVI HIV and AIDS Vaccine Sales by Product in 2024
11.5.6 IAVI HIV and AIDS Vaccine Sales by Application in 2024
11.5.7 IAVI HIV and AIDS Vaccine Sales by Geographic Area in 2024
11.5.8 IAVI HIV and AIDS Vaccine SWOT Analysis
11.5.9 IAVI Recent Developments
11.6 HKUMed
11.6.1 HKUMed Corporation Information
11.6.2 HKUMed Business Overview
11.6.3 HKUMed HIV and AIDS Vaccine Product Models, Descriptions and Specifications
11.6.4 HKUMed HIV and AIDS Vaccine Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 HKUMed Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 HIV and AIDS Vaccine Industry Chain
12.2 HIV and AIDS Vaccine Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 HIV and AIDS Vaccine Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 HIV and AIDS Vaccine Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 HIV and AIDS Vaccine Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global HIV and AIDS Vaccine Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Johnson and Johnson (Janssen)
Sanofi Pasteur
Uvax Bio
IAVI
AELIX Therapeutics
HKUMed
List of Tables
 Table 1. Global HIV and AIDS Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global HIV and AIDS Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global HIV and AIDS Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global HIV and AIDS Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global HIV and AIDS Vaccine Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global HIV and AIDS Vaccine Sales by Region (2020-2025) & (K Units)
 Table 8. Global HIV and AIDS Vaccine Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global HIV and AIDS Vaccine Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global HIV and AIDS Vaccine Sales Share by Manufacturers (2020-2025)
 Table 12. Global HIV and AIDS Vaccine Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global HIV and AIDS Vaccine Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global HIV and AIDS Vaccine by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in HIV and AIDS Vaccine as of 2024)
 Table 16. Global HIV and AIDS Vaccine Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global HIV and AIDS Vaccine Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers HIV and AIDS Vaccine Manufacturing Base and Headquarters
 Table 19. Global HIV and AIDS Vaccine Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global HIV and AIDS Vaccine Sales by Type (2020-2025) & (K Units)
 Table 23. Global HIV and AIDS Vaccine Sales by Type (2026-2031) & (K Units)
 Table 24. Global HIV and AIDS Vaccine Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global HIV and AIDS Vaccine Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global HIV and AIDS Vaccine ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global HIV and AIDS Vaccine Sales by Application (2020-2025) & (K Units)
 Table 29. Global HIV and AIDS Vaccine Sales by Application (2026-2031) & (K Units)
 Table 30. HIV and AIDS Vaccine High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global HIV and AIDS Vaccine Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global HIV and AIDS Vaccine Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global HIV and AIDS Vaccine ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America HIV and AIDS Vaccine Growth Accelerators and Market Barriers
 Table 37. North America HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America HIV and AIDS Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe HIV and AIDS Vaccine Growth Accelerators and Market Barriers
 Table 40. Europe HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe HIV and AIDS Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific HIV and AIDS Vaccine Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific HIV and AIDS Vaccine Growth Accelerators and Market Barriers
 Table 45. Southeast Asia HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America HIV and AIDS Vaccine Investment Opportunities and Key Challenges
 Table 47. Central and South America HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa HIV and AIDS Vaccine Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa HIV and AIDS Vaccine Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Johnson and Johnson (Janssen) Corporation Information
 Table 51. Johnson and Johnson (Janssen) Description and Major Businesses
 Table 52. Johnson and Johnson (Janssen) Product Models, Descriptions and Specifications
 Table 53. Johnson and Johnson (Janssen) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Johnson and Johnson (Janssen) Sales Value Proportion by Product in 2024
 Table 55. Johnson and Johnson (Janssen) Sales Value Proportion by Application in 2024
 Table 56. Johnson and Johnson (Janssen) Sales Value Proportion by Geographic Area in 2024
 Table 57. Johnson and Johnson (Janssen) HIV and AIDS Vaccine SWOT Analysis
 Table 58. Johnson and Johnson (Janssen) Recent Developments
 Table 59. Sanofi-Pasteur Corporation Information
 Table 60. Sanofi-Pasteur Description and Major Businesses
 Table 61. Sanofi-Pasteur Product Models, Descriptions and Specifications
 Table 62. Sanofi-Pasteur Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Sanofi-Pasteur Sales Value Proportion by Product in 2024
 Table 64. Sanofi-Pasteur Sales Value Proportion by Application in 2024
 Table 65. Sanofi-Pasteur Sales Value Proportion by Geographic Area in 2024
 Table 66. Sanofi-Pasteur HIV and AIDS Vaccine SWOT Analysis
 Table 67. Sanofi-Pasteur Recent Developments
 Table 68. Uvax Bio Corporation Information
 Table 69. Uvax Bio Description and Major Businesses
 Table 70. Uvax Bio Product Models, Descriptions and Specifications
 Table 71. Uvax Bio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 72. Uvax Bio Sales Value Proportion by Product in 2024
 Table 73. Uvax Bio Sales Value Proportion by Application in 2024
 Table 74. Uvax Bio Sales Value Proportion by Geographic Area in 2024
 Table 75. Uvax Bio HIV and AIDS Vaccine SWOT Analysis
 Table 76. Uvax Bio Recent Developments
 Table 77. AELIX Therapeutics Corporation Information
 Table 78. AELIX Therapeutics Description and Major Businesses
 Table 79. AELIX Therapeutics Product Models, Descriptions and Specifications
 Table 80. AELIX Therapeutics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 81. AELIX Therapeutics Sales Value Proportion by Product in 2024
 Table 82. AELIX Therapeutics Sales Value Proportion by Application in 2024
 Table 83. AELIX Therapeutics Sales Value Proportion by Geographic Area in 2024
 Table 84. AELIX Therapeutics HIV and AIDS Vaccine SWOT Analysis
 Table 85. AELIX Therapeutics Recent Developments
 Table 86. IAVI Corporation Information
 Table 87. IAVI Description and Major Businesses
 Table 88. IAVI Product Models, Descriptions and Specifications
 Table 89. IAVI Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 90. IAVI Sales Value Proportion by Product in 2024
 Table 91. IAVI Sales Value Proportion by Application in 2024
 Table 92. IAVI Sales Value Proportion by Geographic Area in 2024
 Table 93. IAVI HIV and AIDS Vaccine SWOT Analysis
 Table 94. IAVI Recent Developments
 Table 95. HKUMed Corporation Information
 Table 96. HKUMed Description and Major Businesses
 Table 97. HKUMed Product Models, Descriptions and Specifications
 Table 98. HKUMed Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 99. HKUMed Recent Developments
 Table 100. Key Raw Materials Distribution
 Table 101. Raw Materials Key Suppliers
 Table 102. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 103. Milestones in Production Technology Evolution
 Table 104. Distributors List
 Table 105. Market Trends and Market Evolution
 Table 106. Market Drivers and Opportunities
 Table 107. Market Challenges, Risks, and Restraints
 Table 108. Research Programs/Design for This Report
 Table 109. Key Data Information from Secondary Sources
 Table 110. Key Data Information from Primary Sources


List of Figures
 Figure 1. HIV and AIDS Vaccine Product Picture
 Figure 2. Global HIV and AIDS Vaccine Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Preventive Vaccine Product Picture
 Figure 4. Therapeutic Vaccine Product Picture
 Figure 5. Global HIV and AIDS Vaccine Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Viral Vector Vaccines
 Figure 7. Recombinant Protein Vaccines
 Figure 8. Nucleic Acid Vaccines (including mRNA Vaccines)
 Figure 9. Other Vaccines
 Figure 10. HIV and AIDS Vaccine Report Years Considered
 Figure 11. Global HIV and AIDS Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 13. Global HIV and AIDS Vaccine Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 14. Global HIV and AIDS Vaccine Revenue Market Share by Region (2020-2031)
 Figure 15. Global HIV and AIDS Vaccine Sales (2020-2031) & (K Units)
 Figure 16. Global HIV and AIDS Vaccine Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 17. Global HIV and AIDS Vaccine Sales Market Share by Region (2020-2031)
 Figure 18. Top 5 and Top 10 Manufacturers HIV and AIDS Vaccine Sales Volume Market Share in 2024
 Figure 19. Global HIV and AIDS Vaccine Revenue Market Share Ranking (2024)
 Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 21. Preventive Vaccine Revenue Market Share by Manufacturer in 2024
 Figure 22. Therapeutic Vaccine Revenue Market Share by Manufacturer in 2024
 Figure 23. Global HIV and AIDS Vaccine Sales Market Share by Type (2020-2031)
 Figure 24. Global HIV and AIDS Vaccine Revenue Market Share by Type (2020-2031)
 Figure 25. Global HIV and AIDS Vaccine Sales Market Share by Application (2020-2031)
 Figure 26. Global HIV and AIDS Vaccine Revenue Market Share by Application (2020-2031)
 Figure 27. North America HIV and AIDS Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 28. North America HIV and AIDS Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. North America Top 5 Manufacturers HIV and AIDS Vaccine Sales Revenue (US$ Million) in 2024
 Figure 30. North America HIV and AIDS Vaccine Sales Volume (K Units) by Type (2020- 2031)
 Figure 31. North America HIV and AIDS Vaccine Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 32. North America HIV and AIDS Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 33. North America HIV and AIDS Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 34. US HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 35. Canada HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 36. Mexico HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 37. Europe HIV and AIDS Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 38. Europe HIV and AIDS Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 39. Europe Top 5 Manufacturers HIV and AIDS Vaccine Sales Revenue (US$ Million) in 2024
 Figure 40. Europe HIV and AIDS Vaccine Sales Volume (K Units) by Type (2020-2031)
 Figure 41. Europe HIV and AIDS Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 42. Europe HIV and AIDS Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 43. Europe HIV and AIDS Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 44. Germany HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 45. France HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 46. U.K. HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 47. Italy HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 48. Russia HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 49. Asia-Pacific HIV and AIDS Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 50. Asia-Pacific HIV and AIDS Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 51. Asia-Pacific Top 8 Manufacturers HIV and AIDS Vaccine Sales Revenue (US$ Million) in 2024
 Figure 52. Asia-Pacific HIV and AIDS Vaccine Sales Volume (K Units) by Type (2020- 2031)
 Figure 53. Asia-Pacific HIV and AIDS Vaccine Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 54. Asia-Pacific HIV and AIDS Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 55. Asia-Pacific HIV and AIDS Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 56. Indonesia HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 57. Japan HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 58. South Korea HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 59. China Taiwan HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 60. India HIV and AIDS Vaccine Revenue (2020-2031) & (US$ Million)
 Figure 61. Central and South America HIV and AIDS Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 62. Central and South America HIV and AIDS Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 63. Central and South America Top 5 Manufacturers HIV and AIDS Vaccine Sales Revenue (US$ Million) in 2024
 Figure 64. Central and South America HIV and AIDS Vaccine Sales Volume (K Units) by Type (2021-2031)
 Figure 65. Central and South America HIV and AIDS Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 66. Central and South America HIV and AIDS Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 67. Central and South America HIV and AIDS Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 68. Brazil HIV and AIDS Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 69. Argentina HIV and AIDS Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 70. Middle East, and Africa HIV and AIDS Vaccine Sales YoY (2020-2031) & (K Units)
 Figure 71. Middle East and Africa HIV and AIDS Vaccine Revenue YoY (2020-2031) & (US$ Million)
 Figure 72. Middle East and Africa Top 5 Manufacturers HIV and AIDS Vaccine Sales Revenue (US$ Million) in 2024
 Figure 73. Middle East and Africa HIV and AIDS Vaccine Sales Volume (K Units) by Type (2021-2031)
 Figure 74. South America HIV and AIDS Vaccine Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 75. Middle East and Africa HIV and AIDS Vaccine Sales Volume (K Units) by Application (2020-2031)
 Figure 76. Middle East and Africa HIV and AIDS Vaccine Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 77. GCC Countries HIV and AIDS Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 78. Turkey HIV and AIDS Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 79. Egypt HIV and AIDS Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 80. South Africa HIV and AIDS Vaccine Revenue (2020-2025) & (US$ Million)
 Figure 81. HIV and AIDS Vaccine Industry Chain Mapping
 Figure 82. Regional HIV and AIDS Vaccine Manufacturing Base Distribution (%)
 Figure 83. Global HIV and AIDS Vaccine Production Market Share by Region (2020-2031)
 Figure 84. HIV and AIDS Vaccine Production Process
 Figure 85. Regional HIV and AIDS Vaccine Production Cost Structure
 Figure 86. Channels of Distribution (Direct Vs Distribution)
 Figure 87. Bottom-up and Top-down Approaches for This Report
 Figure 88. Data Triangulation
 Figure 89. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

Global HIV Vaccine Market Research Report 2025
Global HIV and AIDS Clinical Trials Market Research Report 2025
Global Adult Vaccines Market Research Report 2024
Global HIV Clinical Trials Market Research Report 2025
Global HIV Prevention Drug Market Research Report 2024
Global Multiple Vaccine Market Research Report 2024
Global Vaccines for the Elderly Market Research Report 2024
Global Viral Arthritis Vaccine Market Research Report 2025
Global Human Immunodeficiency Virus Type 1 Market Research Report 2024
Global Artificial Intelligence AI in HIV and AIDS Market Research Report 2024
Global Vaccines For Cattle And Sheep Market Research Report 2024
Global Biopharmaceutical and Vaccines Market Research Report 2024
Global Monkeypox Virus Vaccine Market Research Report 2024
Global Harvest Aids Market Research Report 2025
Global Adult and Pediatric Vaccines Market Research Report 2024
Global Anti AIDs Drug Market Insights Forecast to 2030
Human Vaccine Adjuvants Market
Global Seasonal Vaccines Market Research Report 2024
Global HIV 1 Screening Tests Market Research Report 2025
Global Health Product for Immune Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions